IMPORTANCE Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs would require large outcome trials. Human genetics studies can help prioritize or deprioritize these resource-demanding endeavors.
L ipoprotein lipase (LPL) is an endothelium-bound enzyme that catalyzes the rate-limiting step in the clearance of atherogenic triglyceride-rich particles. 1 There is genetic evidence of a causal link between impaired LPLmediated lipolysis and coronary artery disease. Gain-offunction genetic variants in LPL 2,3 and loss-of-function variants in its intravascular inhibitors ANGPTL3, 4-6 ANGPTL4, 2, 7 and APOC3 8, 9 are associated with lower triglyceride levels and lower coronary disease risk, while loss-of-function variants in LPL 2,3,10 and its natural activator APOA5 11 are associated with higher triglyceride levels and higher coronary risk. Impaired LPL-mediated lipolysis has also been linked to insulin resistance 12 and a higher risk of type 2 diabetes, [12] [13] [14] [15] but the associations of this pathway with glucose metabolism are incompletely understood.
There is growing interest around LPL-mediated lipolysis as a target for pharmacological intervention. Several new medicines that enhance LPL-mediated clearance of triglyceriderich lipoprotein particles by directly activating LPL 16, 17 or by inhibiting its intravascular inhibitors 6, 7, [18] [19] [20] are in preclinical 7, 16, 17 or early clinical 6,18-21 development for cardiovascular prevention. However, it is not known whether these agents will provide further benefits in addition to lowdensity lipoprotein cholesterol (LDL-C)-lowering therapy, which is the mainstay of lipid-lowering therapy in cardiovascular prevention. Drugs that accelerate LPL-mediated clearance of triglyceride-rich lipoprotein particles are being developed for use in addition to statins and, possibly, other LDL-Clowering agents. However, statins, 22 ezetimibe, 23 and PCSK9 inhibitors [24] [25] [26] [27] also reduce triglyceride-rich particles, and this could limit the clinical benefits and utility of LPL-enhancing agents when used in combination with these drugs.
Large-scale clinical trials and the investment of massive resources would be required to study the effect of each of these LPL-enhancing agents on cardiovascular outcomes in the context of LDL-C-lowering therapy. In advance of outcome trials, human genetic approaches can provide evidence of whether or not genetically determined differences in LPL-mediated lipolysis and LDL-C metabolism have independent associations with cardiometabolic disease risk, which can help prioritize or deprioritize these resourceintensive efforts. 28, 29 Methods
Study Design
The aims of this study were to (1) investigate associations of genetically enhanced LPL-mediated lipolysis with cardiometabolic risk factors, coronary artery disease, and type 2 diabetes (eFigure 1A in the Supplement), and (2) estimate the independent and combined associations with cardiometabolic outcomes of genetically enhanced LPL-mediated lipolysis and LDL-C-lowering genetic variants (eFigure 1B and C in the Supplement). For the first aim, we estimated associations from summary-level genetic data including up to 672 505 individuals in nonstratified analyses (eFigure 1A in the Supplement). For the second aim, we used individual-level genetic data from up to 390 470 individuals from a pool of 392 220 individuals to perform 2 × 2 factorial (eFigure 1B in the Supplement)or stratified (eFigure 1C in the Supplement) genetic analyses. We also investigated the associations of naturally occurring variation in the genes encoding LPL inhibitors with cardiometabolic outcomes.
Participants and Studies
In nonstratified analyses (eFigure 1A in the Supplement), we used genetic association data on up to 672 505 people from the European Prospective Investigation Into Cancer and Nutrition (EPIC)-InterAct, 30 EPIC-Norfolk, 31 UK Biobank, 32 and large-scale genetic consortia, including the Coronary Artery Disease Genome-Wide Replication and Meta-analysis Plus the Coronary Artery Disease Genetics Consortium (CARDIoGRAMplusC4D), 33 Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium, 34 Genetic Investigation of Anthropometric Traits (GIANT) consortium, 35, 36 Metaanalyses of Glucose and Insulin-Related Traits Consortium (MAGIC), 37, 38 and Global Lipids Genetics Consortium (GLGC). 39 In factorial and stratified analyses (eFigure 1B and C in the Supplement), we used individual-level data from up to 390 470 individuals from a pool of 392 220 individuals included in EPIC-InterAct, EPIC-Norfolk, and UK Biobank (Table) . EPIC-InterAct 30 is a case-cohort study of type 2 diabetes nested within the EPIC study. 40 EPIC-Norfolk is a prospective cohort study of more than 20 000 individuals aged 40 to 79 years living in Norfolk county in the United Kingdom at recruitment. 31 UK Biobank is a population-based cohort of 500 000 people aged 40 to 69 years who were recruited from 2006 to 2010 from several centers across the United Kingdom. 32 Detailed characteristics of the participants with individual-level genotype data included in this study are presented in the Table, and details about the cohorts participating in each analysis, phenotype definitions, and data sources are in eAppendix 1 and eTable 1intheSupplement. All studies were approved by local institutional review boards and ethics committees, and partici-pants gave written informed consent for collection of samples and genetic analysis.
Factorial and Stratified Genetic Analyses
The similarities between the random allocation of genetic variants at conception and that of participants in a randomized trial 41 have been used as rationale to study associations of alleles in different genes to gain insights into the likely consequences of the pharmacological modulation of the gene products in a way that simulates a factorial randomized clinical trial. 42, 43 In this study, for each participant, we calculated a weighted LPL genetic score and a weighted LDL-C genetic score by adding the number of triglyceride-lowering LPL alleles or LDL-C-lowering alleles at 58 LDL-C-associated genetic loci, weighted by their effect on the corresponding lipid levels. These genetic scores were dichotomized at the median value to naturally randomize participants into 4 groups: (1) a reference group, (2) a group with genetically lower triglyceride levels via LPL alleles, (3) a group with genetically lower LDL-C levels via alleles at 58 independent genetic loci, and (4) a group with both genetically lower triglyceride levels via LPL alleles and genetically lower LDL-C levels via the 58 genetic loci. We studied associations with lipid traits and cardiometabolic outcomes between groups using a 2 × 2 factorial design (eFigure 1B in the Supplement). Further details about this approach are in eMethods 1 in the Supplement.
In stratified analyses (eFigure 1C in the Supplement), we studied the associations of LPL alleles with cardiometabolic outcomes in quantiles of the population distribution of 58 LDL-C-lowering alleles or alleles at 3 genes encoding the targets of current lipid-lowering therapy, including HMGCR (encoding the target of statins), NPC1L1 (ezetimibe), and PCSK9 (PCSK9 inhibitors). We considered groups above or below the median of overall and gene-specific LDL-C-lowering genetic scores as well as quintiles of the general LDL-C-lowering genetic score.
Selection of Genetic Variants
As a proxy for genetically enhanced LPL lipolysis, we used 6 genetic variants in the LPL gene previously reported to be strongly and independently associated with triglyceride levels (P <5.0×10 −8 for each variant in conditional analyses from the GLGC 10 ) (eTable 2 in the Supplement). In factorial or stratified analyses, as instruments for genetically lower LDL-C, we used 58 genetic variants from independent genomic regions associated with LDL-C levels in up to 188 577 participants of GLGC 39 (P <5.0×10 −8 for LDL-C in each region; all variants were more than 500 kb away from each other and had low linkage disequilibrium, with pairwise R 2 < 0.01) (eTable 2 in the Supplement). In sensitivity analyses, we used a subset of 22 of the 58 variants that were not associated with triglyceride level in GLGC. 39 We also considered 6 HMGCR, 43 5 NPC1L1, 42 
Loss-of-Function Variants in the Inhibitors of LPL
We estimated associations with cardiometabolic outcomes of a low-frequency variant in ANGPTL4 (p.Glu40Lys; 40Lys allele frequency, 1.9%). The 40Lys allele disrupts the inhibitory effect of ANGPTL4 on LPL in vitro 44 and is strongly associated with lower triglyceride levels (approximately 0.27 SDs lower triglycerides per 40Lys allele; P =4.2×10 −175 ) but not with LDL-C (approximately 0.004 SDs lower LDL-C per 40Lys allele; P = .70) in GLGC. 14 The variant is also associated with protection from cardiometabolic disease. 2, 7, 14, 45 Rare loss-of-function alleles in the LPL inhibitor ANGPTL3 are associated with lower LDL-C and triglyceride levels, 4-6 offering a unique genetic model for the combined reduction of LDL-C levels and enhancement of LPL-mediated lipolysis. Genetic studies and clinical trials show that different LDL-Clowering mechanisms protect against coronary disease with a log-linear relationship that is observed independently of the mechanism by which this reduction is attained. 42, 46, 47 If the association with lower risk of ANGPTL3 variants is only via lower LDL-C levels, one would expect their association to be the same as that of LDL-C-lowering variants in other genes for a given genetic difference in LDL-C levels. We investigated this hypothesis by meta-analyzing and modeling data from previously published genetic studies 5, 6 about the association of rare loss-of-function variants of ANGPTL3 with LDL-C and coronary disease risk (eAppendix 2 in the Supplement). We also attempted to estimate the associations with cardiometabolic outcomes of a rare loss-of-function variant in the APOC3 gene captured by direct genotyping in UK Biobank, but the analysis was uninformative likely because of low statistical power (eAppendix 3 in the Supplement).
Statistical Analysis
In nonstratified and stratified genetic analyses, associations of the 6 triglyceride-lowering genetic variants in LPL with outcomes were estimated using weighted generalized linear regression models that accounted for correlation between genetic variants. 48 Estimates of the association of LPL alleles with triglyceride levels and of LPL alleles with a given outcome were used to calculate estimates of the association of genetically lower triglyceride levels via LPL alleles with that outcome. Correlation values were obtained from the LDlink software (eTable 3 in the Supplement). 49 Results were scaled to represent the β coefficient or the odds ratio (OR) per SD genetically lower triglyceride levels via LPL alleles. Triglyceride associations are expressed in natural log-transformed and standardized units. In factorial genetic analyses (eFigure 1B in the Supplement), the associations of each group relative to the reference group were estimated using linear regression for plasma LDL-C and triglyceride levels and either logistic or Prenticeweighted Cox regression (as appropriate for the study design) for coronary artery disease and type 2 diabetes. All analyses were adjusted for age, sex, and genetic principal components. Analyses were conducted within each study and pooled using fixed-effect inverse varianceweighted meta-analysis. Statistical analyses were performed using Stata version 14.2 (StataCorp) and R version 3.2.2 (The R Foundation for Statistical Computing). A 2-tailed P value less than .05 was considered statistically significant.
Results

Associations of LPL Alleles With Cardiometabolic Risk Factors and Outcomes
Triglyceride-lowering alleles in LPL were associated with lower risk of type 2 diabetes both in combined analyses (OR per SD of genetically lower triglycerides, 0.69; 95% CI, 0.62-0.76; P =2. 6×10 −13 ) (eFigure 2 and eTable 4 in the Supplement) and individual-variant analyses (eFigure 3 and eTable 5i nt h eSupplement). Comparisons with estimates from multiple triglyceride-lowering genetic mechanisms 50 showed that this association is specific to LPL and does not reflect a general association in a protective direction of lower triglyceride levels (eAppendix 4 and eTable 6 in the Supplement). Associations with lower coronary risk (OR per SD of genetically lower triglycerides, 0.59; 95% CI, 0.53-0.66; P =1. 3×10 −22 ) (eFigures 2 and 3 and eTables 4 and 5 in the Supplement) were consistent with previous studies. 10 Triglyceride-lowering LPL alleles were associated with lower fasting insulin levels, fasting plasma glucose levels, and body mass index-adjusted waist-to-hip ratio (ie, a more favorable fat distribution; β in SD of body mass indexadjusted waist-to-hip ratio per SD of genetically lower triglycerides, −0.09; 95% CI, −0.12 to −0.06; P =7 . 9×1 0 −5 ) (eFigure 2 in the Supplement), a novel association consistent with evidence of the preferential LPL-mediated lipid distribution to peripheral, rather than central, adipocytes. 51
Independent and Combined Associations of LPL Alleles and LDL-C-Lowering Alleles With Cardiometabolic Outcomes
In factorial genetic analyses, people naturally randomized to genetically lower triglycerides via LPL alleles had lower triglyceride levels but similar LDL-C levels compared with the reference group (eFigure 4 in the Supplement). The association with lipid levels was additive to that of LDL-C-lowering alleles (eFigure 4 in the Supplement), which were also associated with lower triglyceride levels, consistent with the observed reduction in triglyceride-rich particles in people taking statins, 22 ezetimibe, 23 or PCSK9 inhibitors. [24] [25] [26] [27] People naturally randomized to lower LDL-C levels, lower triglyceride levels via LPL alleles, or both had a lower risk of coronary artery disease compared with the reference group, with the lowest odds in people naturally randomized to both genetic exposures (OR, 0.73; 95% CI, 0.70-0.76; 7% (95% CI, 1%-12%) lower than expected on the basis of the association of the 2 exposures alone (P for interaction = .02). However, stratified analyses in groups above or below the median or in quintiles of the distribution of LDL-C-lowering alleles were not consistent with an interaction (Figure 2A Associations of each genetic score group with risk of coronary artery disease and type 2 diabetes compared with the reference group. The reference group includes those with a low-density lipoprotein cholesterol (LDL-C)-lowering score and a triglyceride-lowering LPL score less than or equal to the median score; the genetically lower triglyceride levels only group, those with a triglyceride-lowering LPL score greater than the median but an LDL-C-lowering score less than or equal to the median; the genetically lower LDL-C levels only group, those with an LDL-C-lowering score greater than the median but a triglyceride-lowering LPL score less than or equal to the median; and the group with both exposures, those with both scores greater than the median. Analyses include individual-level genetic data from 390 470 participants of the UK Biobank, 32 EPIC-Norfolk, 31 People naturally randomized to lower LDL-C had a higher risk of type 2 diabetes compared with the reference group (Figure 1) , consistent with previous studies. 43,50,52-55 However, people naturally randomized to both genetic exposures had a similar risk of type 2 diabetes compared with the reference group (Figure 1 ), as the association of LPL alleles with lower risk cancelled out the risk-increasing association of LDL-C-lowering alleles. Consistently, triglyceride-lowering LPL alleles were strongly associated with lower diabetes risk also in people with genetically lower LDL-C levels (Figure 2A ).
In stratified analyses, triglyceride-lowering LPL alleles were strongly and consistently associated with protection from coronary disease and diabetes in subgroups of people above or below the median of the population distribution of the 58 LDL-C-lowering alleles (Figure 2A 
Evidence From ANGPTL4 and ANGPTL3 Genetic Variants
The ANGPTL4 p.Glu40Lys variant was associated with protection from coronary disease and diabetes, with effect estimates nearly identical to the ones of triglyceride-lowering alleles in LPL for a given genetic difference in triglyceride levels ( Figure 4A ) (eFigure 2 in the Supplement). Associations were consistent in people above or below the median of the 58variant LDL-C-lowering genetic score ( Figure 4A ). Also, the 40Lys allele was associated with a more favorable fat distribution in the UK Biobank (n = 350 450; SD of body mass indexadjusted waist-to-hip ratio per allele, −0.024; SE, 0.0086; P = .005).
In previous sequencing studies, carrying a rare loss-offunction variant in ANGPTL3 has been associated with 36-mg/dL (to convert to millimoles per liter, multiply by 0.0113) lower triglyceride levels and 0.23-SD lower LDL-C levels (approximately 9 mg/dL). 6 In this study, for variants at HMGCR, NPC1L1, and PCSK9 and for the 58-variant LDL-C-lowering genetic score, a genetic difference of 0.23 SD in LDL-C was consistently associated with approximately 10% lower odds of coronary disease (OR, 0.90; 95% CI, 0.89-0.91; I 2 = 0%; P for heterogeneity in effect estimates = .86) (eFigure 7 in the Supplement). In a meta-analysis of published genetic studies 5,6 on rare loss-of-function variants in ANGPTL3, we found an association with approximately 34% lower odds of coronary disease for carriers compared with noncarriers (OR, 0.66; 95% CI, 0.52-0.83; P < .001; I 2 = 0%; P for heterogeneity = .99) (eFigure 8 in the Supplement). For a given genetic difference in LDL-C level, the association of ANGPTL3 variants with lower coronary disease risk was stronger than that of the LDL-Clowering genetic score (P for heterogeneity = .009) ( Figure 4B Data are from the UK Biobank, 32 EPIC-Norfolk, 31 and EPIC-InterAct 30 studies. Median values and interquartile ranges for lipid levels within each stratum are from the EPIC-Norfolk study. To convert LDL-C level to micromoles per liter, multiply by 0.0259. To convert triglyceride level to micromoles per liter, multiply by 0.0113. IQR, interquartile range; OR, odds ratio.
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Discussion
By analyzing individual-level genetic data in close to 400 000 people, we provide strong evidence that triglyceride-lowering alleles in the LPL pathway and LDL-C-lowering genetic mechanisms are independently associated with a lower risk of coronary artery disease. This is of relevance to the future clinical development and positioning of LPL-enhancing drugs, given that these agents are being developed for use in addition to statins and other existing LDL-C-lowering drugs. Because the LDL-C-lowering alleles studied here included those at genes encoding the targets of current LDL-C-lowering therapy, this study supports the hypothesis that pharmacologically enhancing LPL-mediated lipolysis is likely to provide further cardiovascular benefits in addition to existing LDL-C-lowering agents. By studying the interplay of these pathways with a study design that is directly relevant to the future clinical development of LPL-enhancing agents, this study adds to previous analyses that have investigated the associations of LPL pathway alleles 2,3,10,12,14 or LDL-C-lowering alleles 50,53,56-58 with cardiometabolic disease separately. The independent associations with cardiometabolic outcomes of genetically enhanced LPL-mediated lipolysis and of mechanisms that lower LDL-C via PCSK9, NPC1L1, and HMGCR provide direct support for the development of direct enhancers of LPL 16, 17 for use in the context of existing LDL-C-lowering therapy. They also provide general support for other agents that enhance LPL activity via inhibition of its natural inhibitors in this therapeutic context. 6, 7, [18] [19] [20] [21] We also investigated variation at 2 intravascular inhibitors of LPL, ANGPTL4 and ANGPTL3, making 2 important observations. First, the level of protection from coronary disease and diabetes associated with the ANGPTL4 p.Glu40Lys variant is the same as that of LPL alleles for a given genetic difference in triglyceride levels and is consistent across the population distribution of LDL-C-lowering alleles. These findings are relevant for drugs that inhibit ANGPTL4 7 or directly enhance LPL by disrupting the inhibitory activity of ANGPTL4. 17 Second, rare loss-offunction variants in ANGPTL3 are associated with a greater level 
A, Associations of the ANGPTL4 p.Glu40Lys loss-of-function allele with cardiometabolic disease outcomes. Groups with genetically higher or lower low-density lipoprotein cholesterol (LDL-C) levels were defined on the basis of the median value of the 58-variant LDL-C-lowering genetic score. Associations are scaled to represent the odds ratio (OR) per SD of genetically lower triglyceride levels. Data are from the UK Biobank, 32 EPIC-Norfolk, 31 and EPIC-InterAct 30 studies. B, Associations of different genetic exposures associated with lower LDL-C levels with protection against coronary disease.
A clear log-linear relationship between genetic difference in LDL-C level and lower risk is observed for several mechanisms, while ANGPTL3 loss-of-function variants are outliers in this relationship. For individual variants, the estimates represent per-allele differences; for quintiles of the LDL-C score, the difference is compared with the bottom quintile; for the overall genetic score, the difference is per SD of genetically lower LDL-C level; and for ANGPTL3 variants, the difference is in carriers compared with noncarriers.
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Original Investigation Research jamacardiology.com (Reprinted) JAMA Cardiology October 2018 Volume 3, Number 10 of protection from coronary disease than other genetic mechanisms for a given genetic difference in LDL-C levels. This result suggests that ANGPTL3 inhibition may be an exception to the LDL paradigm, the mechanism-independent log-linear relationship between LDL-C lowering and coronary disease protection that has been consistently found in genetic studies and clinical trials. 42, 46 In phase 1 trials, ANGPTL3 inhibitors reduced LDL-C levels by amounts similar to or greater than currently approved LDL-C-lowering drugs. 6, 20, 21 Our findings suggest that ANGPTL3 inhibitors may be more effective than current agents for a given magnitude of LDL-C reduction. Triglyceride-lowering LPL alleles were also associated with protection against type 2 diabetes. The strong and consistent association of multiple independent LPL alleles with lower risk of type 2 diabetes found in our study extends and reinforces previous reports by us and others limited to the rs1801177 12 and rs328 12, 14, 15 alleles. We also provide evidence consistent with the association with lower odds of diabetes being specific to the LPL pathway and not being a general association of lower triglyceride levels. In factorial analyses, this association was in a protective direction with a magnitude equivalent to the association of LDL-Clowering alleles with increased risk of type 2 diabetes. Therefore, our data suggest that enhancing LPL activity may also ameliorate glucose metabolism while further reducing the risk of cardiovascular disease in people taking LDL-C-lowering therapy.
Triglyceride-lowering alleles in LPL were also associated with greater insulin sensitivity, lower glucose levels, and a more favorable body fat distribution pattern, strengthening the link of this pathway with insulin and glucose metabolism. 12, 45 The novel finding from this study of robust associations of triglyceride-lowering LPL alleles and the ANGPTL4 p.Glu40Lys variant with a lower waist-to-hip ratio is consistent with the known role of LPL as a lipidbuffering molecule 51 and corroborates the notion that the association of this pathway with insulin sensitivity and lower diabetes risk may be at least partially because of improved capacity to preferentially store excess calories in peripheral adipose compartments. 12 Limitations A number of assumptions and possible limitations of the genetic approach used in this study are worth considering when interpreting its results. Mendelian randomization generally assumes that genetic variants are associated with the end point exclusively via the risk factor of interest. 41 In this case, the risk factor of interest is genetic differences in LPL-mediated lipolysis, of which triglyceride levels are a proxy, and therefore, the association of LPL alleles with different metabolic risk factors and diseases does not invalidate the approach. The consequences of modest genetically determined differences in LPL-mediated lipolysis over several decades as assessed in this study may differ from the short-term pharmacological modulation of LPL-mediated lipolysis in randomized clinical trials or clinical practice. While our analyses show a strong association of LPL alleles with coronary disease and diabetes, this does not necessarily mean that pharmacologically enhancing lipolysis over a short time will yield clinically relevant changes in future risk of coronary disease or new-onset diabetes in highrisk adults for whom these agents are being developed. Therefore, the effect estimates from our genetic analysis reflect a lifelong exposure to genetic differences in LPL-mediated lipolysis and should not be interpreted as an exact prediction of the magnitude of the clinical effect for studies of the short-term pharmacological modulation of this pathway.
Conclusions
Triglyceride-lowering alleles in the LPL pathway are associated with lower risk of coronary disease and type 2 diabetes independently of LDL-C-lowering genetic mechanisms. These findings provide human genetics evidence to support the development of agents that enhance LPL-mediated lipolysis for further clinical benefit in addition to LDL-C-lowering therapy. This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods 1. Factorial and stratified genetic analyses
Factorial genetic analysis
Factorial genetic analyses (eFigure 1B) were conducted in each of the UK Biobank, EPIC-InterAct or EPIC-Norfolk studies separately and then results were combined using inverse variance-weighted fixed-effect meta-analysis.
We constructed two independent LPL and LDL-C weighted genetic risk scores with two distinct goals: (1) to overcome the weak individual associations of genetic variants with lipid levels and disease risk and (2) to "naturally-randomize" participants into approximately equally sized groups, which ensures the greatest statistical power for these individual-level analyses and is akin to a factorial randomized controlled trial design.
We constructed these genetic scores to estimate the combined and independent association of triglyceride-lowering LPL-alleles and of LDL-C lowering polymorphisms at 58 genetic loci with (a) circulating lipid levels and (b) the risk of coronary artery disease and type 2 diabetes (eFigure 1B). We selected six genetic variants for inclusion in the LPL genetic score that were previously reported to be independently and strongly associated with triglyceride levels in analyses of the Global Lipids Genetics Consortium. 17 All genetic variants satisfied these criteria: (1) were in the LPL gene or within 10 kb of the gene; (2) were independently and strongly associated with triglyceride levels in conditional analyses of the Global Lipids Genetics Consortium with p < 5 x 10 -8 . In parallel, we built a LDL-C lowering genetic risk score using 58 genetic variants at 58 independent genetic loci reported by the Global Lipids Genetics Consortium 12 to be strongly and independently associated with LDL-C levels. All genetic variants satisfied these criteria: (1) were over 500 kb away from each other and had no or negligible linkage disequilibrium (R 2 < 0.01); (2) the genetic regions were associated with LDL-C levels (p < 5 x 10 -8 ) in the Global Lipids Genetics Consortium analysis of up to 188,577 individuals.
For each participant and each genetic variant, we weighted the number of effect alleles (i.e. the triglyceride-lowering allele for LPL variants or the LDL-C lowering allele for the 58 LDL-C associated variants) for the effect on the respective lipid trait expressed in standardised units. We then dichotomised each score by dividing people in a group below or equal to the median and above the median value of the weighted score. Because polymorphisms included in genetic scores are inherited approximately randomly at the time of conception in a process known as "Mendelian randomisation", 18 and inherited approximately independently of the other polymorphisms included in the genetic score, the number of lipid lowering alleles that a person inherits for each genetic score should also be random. Therefore, partitioning the population into two groups should "naturally randomise" the population into two approximately equal groups with different genetically-determined lipid levels.
The dichotomised LPL and LDL-C genetic risk scores were used to naturally randomise participants into 4 groups: (1) reference, (2) genetically-lower triglycerides via LPL-alleles, (3) genetically-lower LDL-C via alleles at 58 independent genetic loci, or (4) both genetically-lower triglycerides via LPL-alleles and genetically-lower LDL-C via the 58 genetic loci (referred to as the group "naturally-randomised to both genetic exposures" for simplicity). The reference group included people below or equal to the median of both lipidlowering genetic scores. The group "genetically-lower triglycerides via LPL-alleles" included people above the median for the triglyceride-lowering LPL score, but below or equal to the median for the LDL-C lowering score. The group "genetically-lower LDL-C" included people below or equal to the median for the triglyceride-lowering LPL score, but above the median for the LDL-C lowering score. The group "naturally-randomised to both genetic exposures" included people above the median for both scores.
Using the four "naturally randomised" groups constructed as described above, the effects of each group relative to the reference group were estimated using linear regression for LDL-C and triglyceride levels, while the association with coronary artery disease and type 2 diabetes was estimated using logistic regression (for combined prevalent and incident outcomes, i.e. in UK Biobank and EPIC-Norfolk) or Cox proportional hazards models (for incident events, i.e. in the EPIC-InterAct study). All analyses were adjusted for age, sex and the first four genetic principal components.
Stratified genetic analyses
In stratified genetic analyses (eFigure 1C), we investigated the association of LPLgenetic variants with type 2 diabetes and coronary artery disease in strata of the population distribution of LDL-C lowering genetic variants. These included variants at HMGCR (encoding the target of statins), NPC1L1 (encoding the target of ezetimibe) and PCSK9 (encoding the target of PCSK9 inhibitors), the 58-variant genetic score and the 22-variant genetic score (after excluding variants associated with triglyceride levels). For each of these genes, we used sets of previously published LDL-C lowering genetic variants which were shown by Ference et al. to be strongly associated with lower LDL-C levels and lower coronary disease risk in previous genetic analyses. 19, 20 We used six approximately independent genetic variants at the HMGCR locus, five approximately independent genetic variants at the NPC1L1 locus and seven approximately independent genetic variants at the PCSK9 locus. 19, 20 We used these genetic variants to partition the population in two groups below or above the median of LDL-C lowering alleles (weighted for their association with LDL-C) at each locus or at the 58 or 22 loci. Additional analyses were conducted in quintiles of the 58-variant LDL-C lowering genetic score. People above the median (or in higher quinitiles) can be thought of as a group of individuals naturally randomised to lower LDL-C levels due to genetic variants at HMGCR, NPC1L1 or PCKS9 or the 58 loci, respectively, serving as a proxy for treatment with the corresponding LDL-C lowering drug or general reduction of LDL-C levels via multiple mechanisms. Within each of these resulting groups, we then estimated the associations of the six triglyceride lowering alleles at LPL with type 2 diabetes and coronary artery disease. We combined individual LPL genetic variant estimates using a weighted generalised linear regression method that accounts for the correlation between genetic variants. 21
eMethods 2. Checks of the quality of genetic data
A number of quality control procedures were used to ensure the quality of genetic data and genetic analyses presented here.
In UK Biobank, EPIC-Norfolk and the Illumina Core-Exome-genotyped subset of EPIC-InterAct, the six LPL genetic were directly genotyped with high-quality using genome-wide genotyping arrays. In the Illumina 660w quad genotyped subset of EPIC-InterAct, rs10096633 was directly genotyped and the other five genetic variants were imputed with minimum imputation accuracy info score of 0.91 (with a score of 1 indicating direct genotyping or perfect imputation). Genotyping in these studies underwent a number of quality control procedures including (a) routine quality checks carried out during the process of sample retrieval, DNA extraction, and genotype calling; (b) checks for genotype batch effects, plate effects, departures from Hardy-Weinberg equilibrium, sex effects, array effects, and discordance across control replicates; (c) individual and genetic variant call rate filters.
Given that UK Biobank was the largest study included in the analysis and that genetic data on close to 500,000 individuals have been recently released, we performed additional checks of the quality of data in addition to those implemented by the UK Biobank team (described in details by Bycroft and colleagues 7 ). Firstly, 58 out of 82 genetic variants included in the analysis were directly genotyped in UK Biobank and cleared all pre-release quality control filters 7 as well as a further filter for >95% call rate. The remaining genetic variants were all imputed using the Haplotype Reference Consortium. Among the 89 genetic variants, the median imputation accuracy info score was 1 (with a score of 1 indicating direct genotyping or perfect imputation) and the median among 24 imputed genetic variants was 1 (minimum score 0.93), indicating excellent imputation. Because the 58 directly-genotyped genetic variants were also imputed using the Haplotype Reference Consortium, we compared the minor allele frequency in the genotyped and imputed data, finding near identical frequencies (correlation coefficient = 1.00).
For all genetic variants included in the analysis, we automatically aligned the effect allele to be coded as the lipid lowering allele (eTable 2), using automated scripts. The frequency of the coded effect allele was near identical in the UK Biobank, EPIC-Norfolk and EPIC-InterAct studies (correlation coefficients > 0.9987 for each pairwise comparison) and corresponded to what reported in external reference data.
In the meta-analysis of EPIC-Norfolk, EPIC-InterAct and UK Biobank results used for factorial analyses, we observed a high degree of consistency of estimates from the different studies (see Inset Table) .
Inset Table. Consistency of estimates of associations of genetic exposures with lipid traits and cardio-metabolic outcomes in factorial genetic analyses presented in this study. The I 2 and p-value for heterogeneity were used to estimate possible heterogeneity. Abbreviations: LPL, lipoprotein lipase; LDL-C, low-density lipoprotein cholesterol; CI, confidence interval. a Beta coefficient in standardised unit of outcome for continuous traits or odds ratio for binary outcomes compared to the reference group (i.e. people below or equal to the median of both a triglyceride lowering via LPL genetic score and a LDL-C lowering via 58 loci genetic score).
eAppendix 1. Cohort descriptions and data sources
EPIC-InterAct
EPIC-InterAct 1 is a case-cohort study of incident type 2 diabetes nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 2 a cohort study of ~500,000 European participants followed-up for an average of 8 years. Eight out of the ten EPIC cohorts agreed to take part in EPIC-InterAct leaving 455,680 participants for screening. Individuals were excluded from EPIC-InterAct if they did not have stored blood (n=109,625) or information on diabetes status (n=5,821; 1.3% of participants screened for inclusion). From the remaining 340,234 participants, 12,403 individuals who developed type 2 diabetes during follow-up constituted the incident case group of EPIC-InterAct and a random group of 16,154 individuals free of diabetes at baseline constituted the subcohort group of EPIC-InterAct. 1 Incident type 2 diabetes was defined on the basis of self-report, linkage to primary care registers, secondary care registers, medication use (drug registers), hospital admissions and mortality data. Subcohort participants were previously shown to be representative of eligible EPIC participants within each country. 1 Data on a total of 20,993 participants with available genotyping (with no overlap with DIAGRAM or EPIC-Norfolk) were included in the study. Type 2 diabetes status was available in all participants. Individuals without genotype data were excluded from the study. Participant characteristics are summarised in Table 1 .
UK Biobank
UK Biobank is a population-based cohort of over 500,000 people aged between 40-69 years who were recruited in 2006-2010 from several centres across the United Kingdom. 3 Data from UK Biobank contributed to the analyses of the associations with cardio-metabolic risk factors, type 2 diabetes and coronary artery disease. Waist and hip circumference were measured from participants using a Seca 200cm tape measure, height was measured using a Seca 240cm measure, while weight for the measurement of body mass index (BMI) was collected using a Tanita BC418MA body composition analyser. Type 2 diabetes was defined on the basis of self-reported physician diagnosis at nurse interview or digital questionnaire, age at diagnosis > 36 years, use of oral anti-diabetic medications and electronic health records. 4 Coronary artery disease was defined as either myocardial infarction or coronary disease documented in the participant's medical history at the time of enrolment by a trained nurse or hospitalisation or death involving acute myocardial infarction or its complications (i.e. International Statistical Classification of Diseases and Related Health Problems codes I21, I22 or I23), similar to what previously described. 5, 6 Participant characteristics 3 and genotyping methods 7 have been reported in detail elsewhere. We describe the details of the quality checks of genetic data in eNote 3. Participant characteristics are summarised in Table  1 .
EPIC-Norfolk cohort study
EPIC-Norfolk is a prospective cohort study of over 20,000 individuals aged between 40 and 79 and living in the Norfolk county in the United Kingdom at recruitment. 8 EPIC-Norfolk is a constituent cohort of the European Prospective Investigation of Cancer (EPIC). 2 Data from EPIC-Norfolk contributed to factorial and stratified genetic analyses. Coronary artery disease eAppendix 2. Associations of ANGPTL3 loss-of-function variants with LDL cholesterol level and coronary artery disease
Rare loss-of-function alleles in the LPL-inhibitor ANGPTL3 are associated with lower LDL-C and triglyceride levels, [22] [23] [24] offering a unique genetic model for the combined reduction of LDL-C levels and enhancement of LPL-mediated lipolysis. Genetic studies and clinical trials show that different LDL-C-lowering mechanisms protect against coronary disease with a mechanism-independent log-linear relationship (i.e. the "LDL-C paradigm"). 19, 25, 26 If the protective effect of ANGPTL3 variants is only via LDL-C reduction, one would expect their association to be the same as that of LDL-C lowering variants in other genes, for a given genetic difference in LDL-C levels. We investigated this hypothesis by meta-analyzing and modelling data from previously published genetic studies about the association of rare loss-of-function variants of ANGPTL3 with LDL-C and coronary disease risk. 23, 24 First, we used results from Dewey and colleagues as estimates of the association of rare loss-of-function variants in ANGPTL3 with LDL-C, i.e. 0.23 SD lower LDL-C (~0.23 mmol/L or 9 mg/dL). 23 Second, we estimated the association with coronary artery disease, for a 0.23 SD genetically-lower LDL-C, of LDL-C lowering variants at HMGCR, NPC1L1, PCSK9 or the 58 LDL-C associated loci using data from UK Biobank and CARDIoGRAMplusC4D. Third, we estimated the association with coronary artery disease, for a 0.23 SD genetically-lower LDL-C, of rare loss-of-function variants in ANGPTL3 by meta-analyzing genetic association studies including up to 58,399 cases and 305,796 controls (eFigure 8). 23, 24 Fourth, we tested for heterogeneity between the estimate of the 58 LDL-C lowering alleles and that of ANGPTL3 variants, showing evidence of heterogeneity (eFigure 7). We conducted a number of sensitivity analyses using different estimates for the LDL-C lowering alleles and ANGPTL3 variants (eTable 8). For comparison, we show the consistency of estimates for variants at HMGCR, NPC1L1, PCSK9 with those for the 58 variant LDL-C score (eFigure 7). eAppendix 3. Association of a rare loss-of-function variant in APOC3 with cardiometabolic disease outcomes in UK Biobank Drugs that inhibit APOC3, an inhibitor of LPL-mediated lipolysis, are in early clinical development for the treatment of dyslipidemia. 27, 28 Rare loss-of-function variants in the encoding gene have been used as genetic model to study the likely consequences of pharmacological APOC3 inhibition. 29, 30 These rare variants are imperfectly captured by array genotyping, such that only one of the four variants driving the reported associations was captured by direct genotyping in UK Biobank (rs147210663, p.Ala43Thr, an experimentallyvalidated loss-of-function variant 31 ), but was not available in InterAct or EPIC-Norfolk. Nonetheless, we sought to estimate the associations with cardio-metabolic disease outcomes of this variant in UK Biobank. In 351,285 people with available genotypes, 279 carried the variant (carrier frequency 0.08%). While the carriers had lower risk of type 2 diabetes (odds ratio per copy of the rare variant rs147210663-A allele, 0.78; 95% confidence interval, 0.44-1.36; p=0.38) and coronary disease (odds ratio per copy of the rs147210663-A allele, 0.90; 95% confidence interval, 0.52-1.55; p=0.70) compared to non-carriers, the difference was not statistically significant. Therefore, it was not possible to meaningfully estimate the association of rare loss-of-function variants of APOC3 in strata of the population distribution of LDL-C lowering alleles. Large-scale sequencing studies of the APOC3 gene will be required to estimate this association. Studies investigating the genetic relationship between triglyceride levels and risk of type 2 diabetes have yielded conflicting results. [32] [33] [34] [35] In a comprehensive Mendelian randomization study, White et al. 35 have estimated the genetic association between triglyceride and diabetes, using 140 triglyceride-lowering genetic variants at multiple loci accounting for possible pleiotropic effects by using different methods, including univariate, multivariate and Egger-MR Mendelian randomization analyses. They found inconsistent results between methods, with Egger-MR (a method that is robust to directional pleiotropy) estimates being consistent with a risk-increasing association for triglyceride-lowering alleles, while the two other methods showed no associations. 35 In this study, we observed associations in a protective direction between triglyceride-lowering alleles at LPL and diabetes risk. We asked whether this association was consistent with estimates of the general genetic relationship between triglycerides and diabetes and tested for heterogeneity between our estimates and those from White and colleagues (eTable 6). We found evidence of heterogeneity, suggesting that the protective association at LPL is specific to this gene/pathway. The figure shows associations with lipid traits expressed in standardized units for each group compared to the reference group. Data on lipid traits were from the EPIC-Norfolk study and the EPIC-InterAct study subcohort. Median values and interquartile ranges for lipid levels are from the EPIC-Norfolk study. Abbreviations: N, number of participants; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; LPL, lipoprotein lipase; SD, standard deviation; IQR, interquartile range. 59 (0.41, 0.85 Estimates were nearly identical to those obtained with all six genetic variants (eFigure 2), but less precise (R 2 <0.01; rs268, rs328, rs1801177). Abbreviations: SE, standard error; OR, odds ratio; CI, confidence interval. a The effect allele is the triglyceride-lowering allele. b In the EPIC-Norfolk, EPIC-InterAct and UK Biobank studies. c Data from the Global Lipids Genetics Consortium, except rs268 for which data is from EPIC-Norfolk. d Data from the CARDIoGRAMplusC4D consortium and the UK Biobank study, except rs301 for which data is from UK Biobank. e Data from EPIC-InterAct, DIAGRAM and UK Biobank, except rs268 for which data is from EPIC-InterAct and UK Biobank. eTable 6. Association with type 2 diabetes of triglyceride-lowering genetic variants at the LPL gene or at several triglyceride-associated regions studied by White Abbreviations: OR, odds ratio; CI, confidence interval; LPL, lipoprotein lipase. a PubMed manuscript ID. b Inverse variance weighted Mendelian randomisation is a primary analysis method in Mendelian randomisation analyses; multi-variable Mendelian randomisation is an analysis method that adjusts for estimates on other traits (i.e. HDL and LDL cholesterol in this case); Egger Mendelian randomisation is a sensitivity analysis method that is robust to directional pleiotropy. c Comparison between the estimate for LPL alleles from this study (reference group) and each of the two estimates from White and colleagues using 140 triglyceride-lowering alleles from multiple genetic loci. eTable 7. Sensitivity analysis of the association between triglyceride-lowering LPL alleles and risk of coronary artery disease and type 2 diabetes in people above or below the median of the population distribution of 22 LDL-C-lowering variants associated with LDL-C but not triglyceride levels
Outcome
Estimates were nearly identical to those obtained with all 58 LDL-C genetic variants ( Figure  2A ). Abbreviations: OR, odds ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; IVW, inverse variance weighted method; MR, Mendelian randomization. a Odds ratio for coronary artery disease per 0.23 SD genetically-lower LDL-C. b Heterogeneity p-value for comparison of effect estimates between ANGPTL3 variants and LDL-C lowering score analysis. c Sensitivity analysis excluding estimates from PennCath study 24 to account for any possible overlap with the Penn Medicine Biobank. 23 d Estimate from UK Biobank and CARDIoGRAMplusC4D of the association of 22 variants associated with LDL-C (p<5×10 -08 ) but not triglyceride (p>0.05) levels in GLGC. 12 e Estimate from White and colleagues of the association with coronary disease of 130 single-nucleotide polymorphisms associated with LDL-C -inverse variance weighted method. 35 f Estimate from White and colleagues of the association with coronary disease of 130 single-nucleotide polymorphisms associated with LDL-C -multivariable Mendelian randomization method (adjusted for HDL-C and triglycerides). 35 g Estimate from White and colleagues of the association with coronary disease of 130 single-nucleotide polymorphisms associated with LDL-C -Egger Mendelian randomization method. 35 
Exposure
